Progress of neoadjuvant therapy for high-risk prostate cancer in the era of novel hormonal therapy
10.3969/j.issn.1009-8291.2023.12.017
- VernacularTitle:新型内分泌药物时代下的高危前列腺癌术前新辅助治疗研究进展
- Author:
Shi YAN
1
;
Yasheng ZHU
2
;
Yutian XIAO
1
;
Tao GUO
3
;
Ye WANG
2
;
Xiaomin ZHANG
1
;
Shancheng REN
2
Author Information
1. Department of Urology, The First Affiliated Hospital of Naval Medical University, Shanghai 200433
2. Department of Urology, The Second Affiliated Hospital of Naval Medical University, Shanghai 200003
3. Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China
- Publication Type:Journal Article
- Keywords:
prostate cancer;
high-risk;
novel hormonal therapy;
neoadjuvant therapy;
pathological evaluation;
AKTA;
drug resistance
- From:
Journal of Modern Urology
2023;28(12):1092-1096
- CountryChina
- Language:Chinese
-
Abstract:
In the past, the use of neoadjuvant androgen deprivation therapy (ADT) for prostate cancer did not exhibit survival benefits and was not recommended by the practicing guidelines. In recent years, with the emergence of novel hormonal therapeutics such as Abiraterone, Enzalutamide, Apalutamide and Darolutamide, the interest for neoadjuvant therapy has been reignited. Here, we summarize the four categories of neoadjuvant therapy with new hormonal agents, and discuss how to evaluate the efficacy and explore the molecular mechanism after neoadjuvant therapy.
